We finally found the first morbidity signal of GLP-1s (or lack thereof).

These are life changing drugs, but like plastic we'll see their effects in force within this generation:

> The longer time spent off GLP-1s, the greater the risk of major cardiovascular events—up to 22 percent for those who abstained for two years.

▲

stavros 6 hours ago | parent | next [-]

Doesn't it make sense that, if you were taking a drug that reduces morbidity, you'll get increased morbidity if you stop it?

▲

jryio 6 hours ago | parent [-]

Not if having a heart attack within 1 year at a higher rate is an co-morbidity factor when the primary treatment was for obesity or diabetes (not stating that obesity and heart disease are not positively correlated).

To use a dense analogy: if I stopped brushing my teeth I would not expect to die of gum disease.

	▲	malfist 6 hours ago \| parent [-]
		I don't think you read the study. The people returned to their pre treatment risk profile after ceasing treatment

▲

cthalupa 6 hours ago | parent | prev | next [-]

You are misunderstanding the study (largely because the article heavily misrepresents it, would be my guess)

They do not see an increase against their pre-GLP1 baseline risk - they see a reversal of the cardioprotective benefits the drug provided while they were on it.

▲

TaupeRanger 6 hours ago | parent | prev [-]

You failed to understand the results of the study and quoted a passage that does not in any way support your assertion.